NCT00663208View on ClinicalTrials.gov

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Chronic Hepatitis C
Interventions
DRUG

Daclatasvir

Capsule, Oral, Approximately 182 days from initial dosing

DRUG

Placebo

Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel

Trial Locations (8)

21225

Parexel International Corporation, Baltimore

32809

Orlando Clinical Research Center, Orlando

33169

Elite Research Institute, Miami

78215

Alamo Medical Research, San Antonio

90630

West Coast Clinical Trials, Llc, Cypress

92801

Advanced Clinical Res Inst, Anaheim

06510

Yale University School of Medicine, New Haven

00909

Local Institution, Santurce

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00663208 - A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects | Biotech Hunter | Biotech Hunter